NANOBIOXTIX ANNOUNCES CHANGES  
TO ITS NON EXECUTIVE BOARD

Paris, April 4th 2011 - NANOBIOXTIX the leading nanomedicine firm focused on cancer therapy, announced today the following changes of its Supervisory Board:

- Patrick Langlois has decided to resign from the Supervisory Board where he was Chairman since 2006.
- Laurent Condomine has been elected Chairman of the Supervisory Board. He joined the Board of Nanobiotix in September 2010 to reinforce the company and to help in the translation of its breakthrough technology and products, NanoXray, into value for patients, as well as for Nanobiotix shareholders and its employees.
- Christophe Douat has been elected to the board. He was on the board of Nanobiotix from 2006 to 2009, when he was instrumental in defining the company’s strategy.

“Nanobiotix has a great potential and should become a leading company in the nanomedicine area where the team has shown a unique expertise, I wish Laurent Condomine all the success; I am convinced he will contribute extensively to the future of Nanobiotix” says Patrick Langlois.

“The management wants to express its gratitude to Patrick Langlois who has efficiently guided Nanobiotix during several years. Thanks to Patrick and the support of our shareholders, Nanobiotix has managed to become a leading company in the nanomedicine field” says Dr. Laurent Levy, CEO and co-founder of Nanobiotix.

“Patrick can be pleased and proud of where Nanobiotix is today. During his tenure the company moved from one with a great scientific concept to one about to start clinical trials in man for its lead product. Nanobiotix has benefited from his experience, knowhow and commitment. It is an honor to be appointed Chairman of the Supervisory Board of Nanobiotix. I am committed to work with the Supervisory Board and the Management Board and to take the company to a successful next stage of its development” says Laurent Condomine.

“I have seen few companies that can have such an impact on human health. The powerful combination of its disruptive technology and best in class, visionary team have the potential to revolutionize radiotherapy. I am honored to be back on the board and look forward to contributing. Choosing the right partner to develop and commercialize NanoXRay will be one of our key assignments.” says Christophe Douat

Laurent Condomine, has worked 34 years in the Pharmaceuticals Industry. His last position has been VP Business Development of AstraZeneca in its HQ, based in London. He was in charge of developing the Corporate Strategy of the Group and of delivering its external growth component. He previously held a similar position with ICI when he was involved in the merger of the company in 1993, then with Zeneca where he played a key role in its merger with Astra in 1998. In 2007, he was a key
member of the team in charge of the acquisition, by AstraZeneca, of MedImmune. He retired at the end of 2007. Prior to his move to London, he held managing positions, including CFO, Sales & Marketing Director and CEO, at ICI-Pharma (France). In 1989 he became CEO of ICI-France and joined the ICI Headquarters in London in 1992. Laurent Condomine graduated from HEC School of Management and holds an MBA from INSEAD. Laurent Condomine is non-executive Chairman of ExonHit, a publicly listed French biotech company.

Christophe Douat was already on the board of Nanobiotix from 2006 to 2009, when he was lead investor. He is currently the chairman of Medincell (drug delivery) and a corporate development adviser. As a VC for 10 years, he co-founded the largest European Medical Device fund and brought his strategic skills to many boards both in the US and in Europe, primarily in health sciences. He is also an alumni of the Boston Consulting Group. Prior to this, Mr. Douat spent 12 years in North America in research, industry and small company environments. Mr. Douat graduated from the French Mines/Paris Tech and holds a MS and an MBA.

ABOUT NANOXRAY PLATFORM
Radiotherapy is the second most common treatment in cancer therapy, used in more than 50% of all cancer patients. It is known to be an effective treatment, however the impact of its physical effect is limited by the dose of radiation that healthy tissues will stand, resulting in a narrow therapeutic window, and leaving a huge space for improvement. Nanobiotix has developed a new class of therapeutics based on nanoparticles, **NanoXray™** therapeutics. They consist of inert nanoparticles designed to enter tumor cells. Upon activation by a standard dose of radiation, they release a tremendous amount of energy that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy. By significantly enhancing the power of radiotherapy, they could change the clinical outcome of radiotherapy and may also enable radiotherapy to play a larger role as a curative treatment.

ABOUT NANOBIOТИХ - [www.nanobiotix.com](http://www.nanobiotix.com)
Paris, France, based, Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE). With the development of numerous new compounds, Nanobiotix’s objective is to increase its leading position in nanomedicine field. A major milestone and validation of Nanobiotix approach is its first-in-man clinical study of NanoXray™ therapeutics going to start shortly.

**Nanobiotix Contact**
Dr. Laurent Levy, CEO
Laurent.levy@nanobiotix.com
CEO Blog about nanomedicine

**Press Contact**
Annie-Florence Loyer - afloyer@yucatan.tm.fr
+33 1 53 63 27 29 / +33 6 88 20 35 59
Nadège Le Lezec – nlelezec@yucatan.tm.fr
+33 1 53 63 27 27 / +33 6 89 67 16 51